Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 90 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 30 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 30 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 60 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 90 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 30 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

helm ag - cinakalcet - filmsko obložena tableta - cinakalcet 90 mg / 1 tableta - cinakalcet

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

bayer pharma ag - gadopentetna kislina - raztopina za injiciranje - gadopentetna kislina 274 mg / 1 ml - gadopentetna kislina

Evropska unija - slovenščina - EMA (European Medicines Agency)

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotična sredstva - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.

Evropska unija - slovenščina - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.